share_log

科伦药业:关于子公司核心产品芦康沙妥珠单抗(sac-TMT)基于OptiTROP-Breast01研究治疗2线及以上TNBC获国家药品监督管理局批准上市的公告

Colon Pharmaceutical: Announcement on the subsidiary\'s core product, lukansastuzumab (SAC-TMT) based on Optitrop-Breast01 research and treatment line 2 and above TNBC approved for marketing by the State Drug Administration

SZSI ·  Nov 27
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more